Transform Therapies, Reimagine Lives
Alumis is a clinical-stage biopharmaceutical company advancing a late-stage portfolio of next-generation oral targeted therapies for patients with immune-mediated diseases including psoriasis, lupus, and thyroid eye disease. The company's precision approach leverages proprietary data analytics to optimize clinical outcomes across a broad range of conditions.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountJun 2024
Mar 2024
Jan 2022
Create a free account to see which investors have funded this company.
Create Free Account
Health insurance company using technology to make health care simple, affordable, and accessible.
Provides comprehensive molecular profiling and AI-driven precision oncology services for physicia...
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...
Clinical-stage biotechnology company developing PROTAC protein degraders for oncology and neurode...
R&D company with 6 SBIR/STTR awards from Department of Health and Human Services.
